🇺🇸

US SEC Filing Intelligence

· daily

VA Healthcare & Services Contracts — July 20, 2026

The single contract analyzed, a $190 million firm-fixed-price delivery order from the Department of Veterans Affairs to OptumServe Health Services (UnitedHealth Group subsidiary), represents a purely civilian healthcare services award with no defense exposure. The contract, fully competed and 92.4% executed, signals strong cash flow realization and competitive positioning for OptumServe in the stable VA disability examination market. However, the absence of option periods and the contract's completion in 2021 create recompetition risk. The key watch item is the timing of the next VA Region 2 disability exam solicitation, as this contract is fully mature and no longer generating new revenue.

1 total filings
· daily

New Federal Contractors — July 20, 2026

The three contracts analyzed total $5.2 billion in obligations, all from civilian agencies (0% defense-related), signaling a strong but narrow civilian procurement theme. The dominant signal is Leidos Biomedical Research Inc.'s $4.81B award from HHS, a high-conviction bullish event that dwarfs the other two contracts combined. However, the HHS contract lacks critical details on pricing, competition, and revenue recognition, creating execution risk. The other two contracts—Cardinal Intellectual Property's $191.9M USPTO award and OptumServe's $190M VA order—are neutral, with the latter nearly fully executed. Key risk: the $0 outlay on the 13-year Cardinal contract suggests delayed revenue recognition, while the Leidos award's 2008 start date raises questions about current relevance.

3 total filings
· daily

Significant Contract Modifications ($10M+) — July 20, 2026

The three contracts analyzed total $5.2 billion, all from civilian agencies, with no defense-related awards. The dominant theme is a massive $4.81 billion award to Leidos Biomedical Research from the Department of Health and Human Services, representing the highest-conviction bullish signal despite being a modification to an existing contract. The other two contracts—Cardinal Intellectual Property ($192 million) and OptumServe Health Services ($190 million)—are neutral, with the former carrying execution risk due to zero outlayed funds and the latter nearing completion. Key risks include budget uncertainty from the ongoing Continuing Resolution and the potential for protest or recompetition on the OptumServe contract.

3 total filings
· daily

Contract Deobligations Alert — July 20, 2026

The three contracts analyzed total $5.195 billion, all from civilian agencies with no defense exposure, signaling a significant shift in government spending toward health and intellectual property services. The dominant theme is a massive $4.81 billion Leidos Biomedical Research contract from HHS, which is the highest-conviction signal but lacks pricing and competition details, creating uncertainty. A $191.9 million Cardinal Intellectual Property contract from the USPTO offers long-term revenue visibility but has zero outlayed funds, raising execution risk. The $190 million OptumServe VA contract is nearly fully executed, indicating strong cash flow realization. Key risks include the lack of defense contracts, which may underweight sector exposure, and the need to monitor the Leidos contract's activation and Cardinal's revenue recognition.

3 total filings
· daily

Contract Option Exercises — July 20, 2026

This digest covers $5.2 billion in contract option exercises, all from civilian agencies, with zero defense-related awards. The dominant signal is a massive $4.81B sole-source award to **Leidos Biomedical Research** from the Department of Health and Human Services, representing 93% of total obligation and carrying the highest conviction (bullish, 7/10). This dwarfs two smaller, competitively-won civilian contracts to **Cardinal Intellectual Property** ($192M, USPTO) and **OptumServe** ($190M, VA). The key risk is the lack of defense exposure in a period typically sensitive to Continuing Resolution dynamics, while the key watch item is the activation status of the Leidos Biomedical contract, given its size and potential for revenue recognition delays.

3 total filings
· daily

All HHS Contracts — July 20, 2026

This digest covers a single, massive $4.81B contract awarded to Leidos Biomedical Research Inc. by the Department of Health and Human Services (HHS), a civilian agency. Despite the 'defense contract' label in the raw data, the award is entirely civilian in nature, with zero defense-related contracts in the stream. The dominant theme is a high-conviction, sole-source or long-standing relationship between HHS and Leidos Biomedical, signaling a durable revenue stream for the company. Key risks include the lack of pricing and competition details, which could imply cost-plus risk or protest vulnerability. Investors should monitor this as a potential multi-year program anchor for Leidos' government services segment.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — July 20, 2026

This digest covers three civilian agency contracts totaling $5.2 billion, with zero defense-related awards, signaling a heavy tilt toward health and administrative services. The dominant theme is a massive $4.81B award to Leidos Biomedical Research from HHS, which accounts for 93% of total obligation and represents the highest-conviction signal despite limited data. Neutral signals from Cardinal Intellectual Property ($192M, USPTO) and OptumServe ($190M, VA) indicate competitive wins with execution risks, but the Leidos award alone drives a bullish sector view on biomedical research outsourcing. Key risks include the lack of outlayed funds on the Cardinal contract and the near-complete execution of the OptumServe order, which leaves no near-term revenue runway.

3 total filings
· daily

High-Value Federal Grants ($5M+) — July 20, 2026

This digest covers three high-value federal contracts totaling $5.2 billion, all civilian (0% defense), with a dominant $4.8 billion award to Leidos Biomedical Research Inc. from HHS. The highest-conviction signal is the Leidos award, which is classified as a defense contract from a civilian agency, suggesting potential misclassification or dual-use biomedical research with defense applications. A key risk is the $0 outlayed amount on the $192 million Cardinal Intellectual Property contract, indicating possible delays or non-activation, while the $190 million OptumServe VA contract is nearly fully executed, signaling strong cash flow realization but limited future visibility.

3 total filings
· daily

General Federal Contracts — July 20, 2026

This digest covers three civilian contracts totaling $5.2 billion, with zero defense-related awards, underscoring a heavy tilt toward health and intellectual property services. The dominant signal is Leidos Biomedical Research's $4.81 billion award from HHS, which accounts for 93% of total obligation and carries a bullish 7/10 signal strength, though its defense classification and lack of pricing or competition details introduce uncertainty. Cardinal Intellectual Property's $192 million USPTO contract offers long-term revenue visibility but has zero outlays to date, raising execution risk. OptumServe's $190 million VA award is nearly fully executed, confirming strong performance but signaling recompetition risk. The key watch item is the activation and outlay trajectory of the Leidos contract, given its outsized weight.

3 total filings
· daily

Nasdaq 100 Stocks SEC Filings — July 20, 2026

The single filing from Strategy Inc (STRD) for the week of July 13-19, 2026, reveals a notable pause in the company's aggressive bitcoin acquisition strategy, with no BTC purchases and no preferred stock sales for the first time in recent weeks. The company raised $263.5 million via its ATM program but held the proceeds in its USD Reserve ($3.225 billion), signaling a potential shift to a more cautious capital allocation posture. Despite the pause, the company's massive BTC holdings (843,775 BTC at an average cost of $75,476) and the $21.0 billion MSTR Increase authorization provide a significant future catalyst for further accumulation. The lack of share repurchases under the buyback program suggests management prioritizes BTC acquisition over shareholder returns. This filing, while neutral in sentiment, highlights a critical inflection point: Strategy Inc is accumulating dry powder, which could precede a major BTC purchase or signal a strategic reassessment. The broader NASDAQ-100 context is quiet, but this single data point is highly material for crypto-exposed investors.

1 medium 1 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — July 20, 2026

This digest of 50 SEC filings reveals a landscape dominated by passive institutional positioning and strategic insider accumulation, with notable activist settlements and capital infusions. The most significant development is the settlement between Murchinson Ltd. and Nano Dimension Ltd., ending a proxy fight with board reconstitution and mixed insider trading activity, signaling potential governance improvements but also uncertainty. Several major shareholders, including ReposiTrak's 31.4% stake in SPAR Group and Atlas Capital's $5M private placement in Greenidge, indicate strategic consolidation and capital deployment. Insider buying patterns are evident in Costamare Bulkers (active open-market purchases under a 10b5-1 plan) and Evogene Ltd. (aggressive ADS accumulation), while LGL Group saw a $10.4M rights offering participation by Mario Gabelli. The data shows a bifurcated market: passive institutional investors (Millennium Management, Aberdeen Group) are adjusting positions in biotech and tech, while activist-adjacent funds (Fairmount, Velan Capital) are increasing stakes post-corporate events. Key themes include post-merger stake adjustments, SPAC positioning (Research Alliance Corp IV with three filers), and insider confidence signals through direct purchases.

18 high priority 32 medium 50 total filings
· daily

S&P 500 Financials Sector SEC Filings — July 20, 2026

The three filings from the S&P 500 Financials sector reveal a mixed picture of capital management and insider sentiment. Intercontinental Exchange (ICE) and Robinhood Ventures Fund I both show significant insider selling, with ICE's NYSE Group President executing a large sale under a 10b5-1 plan, while Robinhood's parent company also reduced its stake, signaling potential caution at the top. In contrast, Goldman Sachs is proactively managing its capital structure with a preferred stock offering to refinance higher-cost debt, a neutral but strategically sound move. Period-over-period comparisons are limited in these filings, but the insider activity pattern suggests a bearish tilt among executives in exchange and fintech subsectors. The key themes are insider de-risking and opportunistic capital optimization, with Goldman's refinancing offering a potential yield opportunity for income-focused investors.

2 high priority 1 medium 3 total filings
· daily

S&P 500 Energy Sector SEC Filings — July 20, 2026

The three filings from the S&P 500 Energy sector reveal a bifurcated insider activity pattern: while Kinder Morgan insiders are executing routine tax-related share withholdings under 10b5-1 plans, a 10% owner at Texas Pacific Land Corp made a token purchase, signaling long-term confidence despite a small transaction size. No period-over-period financial trends, forward-looking guidance, or capital allocation changes were reported in these filings, limiting the depth of portfolio-level trend analysis. The insider transactions at Kinder Morgan are non-discretionary and do not indicate management concern, while the Texas Pacific Land buy is a positive but negligible signal. The lack of operational metrics, M&A, or guidance updates across all three filings suggests a quiet period for these energy constituents, with no immediate catalysts or red flags. The key takeaway is that the sector is in a steady state with no material shifts in management sentiment or corporate strategy from these disclosures.

3 high priority 3 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — July 20, 2026

The sole filing in this Consumer Staples digest comes from Hershey Co, revealing a notable insider sale by the 10% owner, Hershey Trust Co, which sold approximately $1.17 million in stock under a 10b5-1 plan. While the sale is pre-planned and not discretionary, the negative sentiment and materiality score of 5/10 warrant attention, especially given the trust's outsized influence as a controlling shareholder. No period-over-period comparisons, forward-looking guidance, or capital allocation data were available in this filing, limiting the ability to assess broader operational trends. The key takeaway is a potential signal of reduced conviction from a major stakeholder, though the 10b5-1 structure mitigates immediate alarm. Investors should monitor for any subsequent filings or earnings calls that might clarify the trust's long-term intentions.

1 high priority 1 total filings
· daily

S&P 500 Industrials Sector SEC Filings — July 20, 2026

The 15 filings from the S&P 500 Industrials stream reveal a sector bifurcating between strong top-line growth and margin pressures. FedEx's 10-K shows a 8% revenue increase to $94.7B, but a 10 bps consolidated margin decline masks a severe 970 bps contraction in its Freight segment, signaling structural headwinds in ground freight. Honeywell and Honeywell Aerospace filings show routine insider stock-for-tax transactions by top executives, including CEO Vimal Kapur and Aerospace CEO James Currier, indicating no unusual conviction signals. Uber Technologies filings also show routine insider RSU conversions and tax withholding by the CFO and other officers, with no open-market buying or selling. The dominant theme is the absence of bullish insider activity and the presence of significant operational stress at FedEx Freight, which should be a key watch item for the broader transportation and logistics sub-sector.

15 high priority 15 total filings
· daily

Insider Trading Pulse — July 20, 2026

Today's insider trading pulse reveals a bifurcated market with significant insider selling by multiple C-suite executives at Sea Ltd, Incyte Corp, and MapLight Therapeutics, contrasting with notable insider buying at Flora Growth Corp and 17 Education & Technology Group. The most material insider sale came from Toyota Motor Corp's Vice Chairman ($1.58M), while the largest buy was Flora Growth's Executive Chairman ($3.48M). A striking pattern emerges with Director Mahai Chris LaVictoire making coordinated purchases across four abrdn healthcare funds, signaling conviction in the healthcare sector. The day is dominated by neutral award filings (stock options, RSUs) which represent routine compensation, but the concentrated selling by CFOs and COOs at Sea Ltd and MapLight warrants close attention. Period-over-period trends from the enriched data show no major revenue or margin shifts reported in these filings, as the focus remains on transaction-level insider activity. The most critical development is the coordinated insider selling at Sea Ltd across three top executives totaling over $1.28M, all under 10b5-1 plans, which may indicate a pre-planned diversification strategy rather than a negative signal.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — July 20, 2026

The 12 filings from Dow 30 constituents are dominated by routine insider transactions at Honeywell and Disney, where executives exercised and withheld shares for taxes—a neutral signal of standard equity compensation, not conviction selling. The sole corporate action is Goldman Sachs' launch of a preferred stock offering to refinance higher-cost Series U preferreds, a capital management move that modestly improves its cost of capital. No period-over-period trends, forward guidance, or capital allocation changes were disclosed in these filings, limiting the ability to extract portfolio-level growth or margin trends. The key takeaway is the absence of material strategic signals: no insider buying, no guidance changes, and no dividend or buyback updates. The Goldman Sachs offering is the only actionable event, signaling a refinancing opportunity that could save ~$15M annually on preferred dividends. Overall, the digest reflects a quiet period for Dow 30 blue chips, with no bullish or bearish catalysts emerging from this batch.

11 high priority 1 medium 12 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 20, 2026

The July 20, 2026 corporate distress landscape is dominated by acute delisting and bankruptcy events, with three of four filings representing severe liquidity or compliance failures. Smart Powerr Corp. (CREG) faces imminent Nasdaq suspension (July 21) and a move to OTCQB, while Sangamo Therapeutics (SGMOQ) has entered Chapter 11 with a forced asset sale deadline of August 4. SES AI Corp (SES) received a NYSE non-compliance notice but has a six-month cure period, offering a more manageable timeline. In contrast, TEN Holdings (XHLD) has temporarily resolved its Nasdaq equity deficiency via a $6.6M offering, though monitoring continues. The period-over-period data reveals no revenue growth or margin trends across these filings, as all are pre-revenue or distressed. Insider activity is absent, and no capital allocation actions (dividends, buybacks) are reported. The overarching theme is a cascade of small-cap biotech and energy companies failing to meet exchange listing standards, with Sangamo's bankruptcy representing the most terminal outcome. The market implication is heightened risk for micro-cap stocks with low liquidity and reliance on equity raises for compliance.

4 high priority 4 total filings
· daily

US SEC Filings Daily Market Digest — July 20, 2026

Today's digest (July 20, 2026) is eventful, dominated by a major SPAC merger filing (DRC Medicine/Ribbon Acquisition), a high-profile IPO (Jersey Mike's Subs), a significant corporate restructuring (Flex Ltd. spin-off), and a mining sector consolidation (Gold Resource Corp/Goldgroup). Enriched period data reveals a clear divergence: consumer-facing names like Domino's Pizza are showing pronounced same-store sales stagnation (US +0.1%, Int'l -0.1%), while assets like Investar Holding Corp demonstrate mixed results with a strong YoY earnings recovery (+98% YoY, albeit down QoQ). A notable cluster of auditor changes and financial restatements create risk flags across micro-cap names like Adapti and Spectral Capital. Insider activity is sparse, with the most material being a newly filed controlling 75% stake in Margaree Acquisition Corp. Capital allocation trends are mixed, with a healthy IPO pipeline and SPAC activity alongside a concerning lack of revenue generation at Alternus Clean Energy. The 13F filings paint a broadly neutral picture, showing large institutional portfolios heavily tilted towards fixed-income ETFs and mega-cap tech, suggesting a 'risk-off but with concentrated bets' stance. Key catalysts to watch include the DRC Medicine SPAC shareholder vote, Jersey Mike's pricing, and the continued MHRA decision for Northwest Biotherapeutics.

11 high priority 39 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — July 20, 2026

The sole filing in this digest, from Centene Corp, involves a routine insider equity award to Director Tyler Lauren M, carrying a neutral sentiment and moderate materiality (6/10). This transaction is a standard compensation grant of 3,155 common stock shares, not a market purchase or sale, and therefore does not signal a change in management conviction. With no other filings in the period, there are no portfolio-level trends, period-over-period comparisons, or sector-wide patterns to synthesize. The digest is limited to this single, non-actionable event, providing no bullish or bearish catalysts for the S&P 500 Healthcare sector.

1 high priority 1 total filings